ESC 2026: Evidence supporting SGLT2 inhibitors and finerenone in heart failure grows

ConferenceSGLT2 inhibitorsfinerenonePositive

AI Analysis

Summary

ESC 2026 conference reports growing evidence supporting SGLT2 inhibitors and finerenone for heart failure treatment. Multiple treatment guidelines worldwide recommend SGLT2 inhibitors for all types of heart failure.

Importance:2/10

Sentiment:

0.50

SGLT2 inhibitorsfinerenoneheart failureESC 2026treatment guidelines

Read the original article

Published by Pharmaceutical Technology on August 31, 2026 9:27 PM

Read Original